[Multiple myeloma: a focus on drugs under development].

Abstract

The introduction of proteasome inhibitors and immunomodulatory and antibody drugs has dramatically improved the prognosis of multiple myeloma (MM) in the 21st century. Despite the development of such highly effective MM therapeutics, however, patients may develop drug resistance and become refractory to standard therapies, and thus cannot be cured. New molecular targeted (venetoclax, selinexor), immunomodulatory (iberdomide), and antibody drugs (isatuximab, belantamab mafodotin), as well as bispecific T-cell engagers (BiTE) and chimeric antigen receptor T-cell (CAR T-cell) therapy, have been developed in the past 1-2 years, and promising results have been reported. In this article, we mainly review these drugs currently under development.

• Authors: Kazutaka Sunami
• Journal: [Rinsho ketsueki] The Japanese journal of clinical hematology (Rinsho Ketsueki) Vol. 61 Issue 5 Pg. 520-527 ( 2020) ISSN: 0485-1439 [Print] Japan
• PMID: 32507818 (Publication Type: Journal Article)

Chemical References

• Proteasome Inhibitors

Topics

• Humans
• Immunotherapy
• Multiple Myeloma (drug therapy)
• Proteasome Inhibitors
• T-Lymphocytes